Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

NCT05112991 is registered in ClinicalTrials.gov with 3D Medicines (Sichuan) Co., Ltd. as lead sponsor.

NCT NCT05112991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05112991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
Lead sponsor
3D Medicines (Sichuan) Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
March 4, 2022
Completion date
December 31, 2026
Enrollment
108 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

advanced endometrial cancer